Akram H, Mokrysz C, Curran HV (2019) What are the psychological effects of using synthetic cannabinoids? A systematic review. J Psychopharmacol 33:271–283
CAS
PubMed
Article
Google Scholar
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596
Angerer V, Franz F, Moosmann B, Bisel P, Auwärter V (2019) 5F-Cumyl-PINACA in ‘e-liquids’ for electronic cigarettes: comprehensive characterization of a new type of synthetic cannabinoid in a trendy product including investigations on the in vitro and in vivo phase I metabolism of 5F-Cumyl-PINACA and its non-fluorinated analog Cumyl-PINACA. Forensic Toxicol 37:186–196
CAS
PubMed
Article
Google Scholar
Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837
PubMed
Article
CAS
Google Scholar
Barratt MJ, Cakic V, Lenton S (2013) Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev 32:141–146
PubMed
Article
Google Scholar
Barratt MJ, Ferris JA, Zahnow R, Palamar JJ, Maier LJ, Winstock AR (2017) Moving on from representativeness: testing the utility of the Global Drug Survey. Subst Abuse 11:1178221817716391
PubMed
PubMed Central
Google Scholar
Bonar EE, Ashrafioun L, Ilgen MA (2014) Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates. Drug Alcohol Depend 143:268–271
PubMed
PubMed Central
Article
Google Scholar
Bonnet U, Preuss UW (2017) The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil 8:9–37
PubMed
PubMed Central
Article
Google Scholar
Budney AJ, Novy PL, Hughes JR (1999) Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94:1311–1322
CAS
PubMed
Article
Google Scholar
Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41
CAS
PubMed
Article
Google Scholar
Cooper ZD (2016) Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep 18:52–52
PubMed
PubMed Central
Article
Google Scholar
Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, Simmons MS, Gorelick DA (2006) Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict 15:8–14
PubMed
Article
Google Scholar
Chandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, Elsohly MA (2019) New trends in cannabis potency in USA and Europe during the last decade (2008–2017). Eur Arch Psychiatry Clin Neurosci 269:5–15
PubMed
Article
Google Scholar
Craft S, Winstock A, Ferris J, Mackie C, Lynskey MT, Freeman TP (2020) Characterising heterogeneity in the use of different cannabis products: latent class analysis with 55 000 people who use cannabis and associations with severity of cannabis dependence. Psychol Med 50:2364–2373
PubMed
Article
Google Scholar
Degenhardt L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, Whiteford H, Leung J, Naghavi M, Griswold M, Rehm J, Hall W, Sartorius B, Scott J, Vollset SE, Knudsen AK, Haro JM, Patton G, Kopec J, Carvalho Malta D, Topor-Madry R, McGrath J, Haagsma J, Allebeck P, Phillips M, Salomon J, Hay S, Foreman K, Lim S, Mokdad A, Smith M, Gakidou E, Murray C, Vos T (2018) The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016. The Lancet Psychiatry 5:987–1012
Article
Google Scholar
Di Forti M, Quattrone D, Freeman TP, Tripoli G, Gayer-Anderson C, Quigley H, Rodriguez V, Jongsma HE, Ferraro L, La Cascia C, La Barbera D, Tarricone I, Berardi D, Szöke A, Arango C, Tortelli A, Velthorst E, Bernardo M, Del-Ben CM, Menezes PR, Selten J-P, Jones PB, Kirkbride JB, Rutten BP, de Haan L, Sham PC, van Os J, Lewis CM, Lynskey M, Morgan C, Murray RM, Group E-GW (2019) The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry 6:427–436
Article
Google Scholar
Durand D, Delgado LL, de la Parra-Pellot DM, Nichols-Vinueza D (2015) Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: a case report. Clin Schizophr Relat Psychoses 8:205–208
PubMed
Article
Google Scholar
EMCDDA (2017) Prospectives on drugs: synthetic cannabinoids in Europe. Publications Office of the European Union, EMCDDA Papers
Google Scholar
EMCDDA (2019a) Developments in the European cannabis market. Publications Office of the European Union, EMCDDA Papers
Google Scholar
EMCDDA (2019b) EU Drug Markets Report 2019. Publications Office of the European Union, EMCDDA Papers
Google Scholar
Ford LT, Berg JD (2018) Analytical evidence to show letters impregnated with novel psychoactive substances are a means of getting drugs to inmates within the UK prison service. Ann Clin Biochem 55:673–678
CAS
PubMed
Article
Google Scholar
Freeman TP, Craft S, Wilson J, Stylianou S, ElSohly M, Di Forti M, Lynskey MT (2021) Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction 116:1000–1010
PubMed
Article
Google Scholar
Freeman TP, Winstock AR (2015) Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med 45:3181–3189
CAS
PubMed
PubMed Central
Article
Google Scholar
Freeman TP, Lorenzetti V (2020) ‘Standard THC units’: a proposal to standardize dose across all cannabis products and methods of administration. Addiction 115: 1207–1216
Google Scholar
Grigg J, Manning V, Arunogiri S, Lubman DI (2019) Synthetic cannabinoid use disorder: an update for general psychiatrists. Aust Psych 27:279–283
Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL (2014) A survey of synthetic cannabinoid consumption by current cannabis users. Subst Abus 35:184–189
PubMed
PubMed Central
Article
Google Scholar
Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF (2008) Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry 69:1354–1363
PubMed
PubMed Central
Article
Google Scholar
Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V (2013) Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 108:534–544
PubMed
Article
Google Scholar
Hines LA, Freeman TP, Gage SH, Zammit S, Hickman M, Cannon M, Munafo M, MacLeod J, Heron J (2020) Association of high-potency cannabis use with mental health and substance use in adolescence. JAMA Psychiat 77:1044–1051
Article
Google Scholar
Lawn W, Barratt M, Williams M, Horne A, Winstock A (2014) The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol 28:780–788
CAS
PubMed
Article
Google Scholar
Livne O, Shmulewitz D, Lev-Ran S, Hasin DS (2019) DSM-5 cannabis withdrawal syndrome: demographic and clinical correlates in U.S. adults. Drug Alcohol Depend 195:170–177
PubMed
Article
Google Scholar
Loeffler G, Delaney E, Hann M (2016) International trends in spice use: prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids. Brain Res Bull 126:8–28
CAS
PubMed
Article
Google Scholar
Macfarlane V, Christie G (2015) Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev 34:147–153
PubMed
Article
Google Scholar
Matias J, Kalamara E, Mathis F, Skarupova K, Noor A, Singleton N (2019) The use of multi-national web surveys for comparative analysis: lessons from the European Web Survey on Drugs. Int J Drug Pol 73:235–244
Article
Google Scholar
Monte AA, Calello DP, Gerona RR, Hamad E, Campleman SL, Brent J, Wax P, Carlson RG (2017) Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: a ToxIC Database Study. J Med Toxicol 13:146–152
CAS
PubMed
PubMed Central
Article
Google Scholar
Nacca N, Vatti D, Sullivan R, Sud P, Su M, Marraffa J (2013) The Synthetic Cannabinoid Withdrawal Syndrome. J Addict Med 7(4):296–298. https://doi.org/10.1097/ADM.0b013e31828e1881
Norman C, Walker G, McKirdy B, McDonald C, Fletcher D, Antonides LH, Sutcliffe OB, Nic Daéid N, McKenzie C (2020) Detection and quantitation of synthetic cannabinoid receptor agonists in infused papers from prisons in a constantly evolving illicit market. Drug Test Anal 12:538–554
CAS
PubMed
Article
Google Scholar
Pirona A, Bo A, Hedrich D, Ferri M, van Gelder N, Giraudon I, Montanari L, Simon R, Mounteney J (2017) New psychoactive substances: current health-related practices and challenges in responding to use and harms in Europe. Int J Drug Pol 40:84–92
Article
Google Scholar
Potter DJ, Hammond K, Tuffnell S, Walker C, Di Forti M (2018) Potency of Δ9–tetrahydrocannabinol and other cannabinoids in cannabis in England in 2016: implications for public health and pharmacology. Drug Test Anal 10:628–635
CAS
PubMed
Article
Google Scholar
Ralphs R, Gray P (2018) New psychoactive substances: new service provider challenges. Drugs: education. Prevent Pol 25:301–312
Google Scholar
Ralphs R, Williams L, Askew R, Norton A (2017) Adding Spice to the Porridge11‘Porridge’ is British slang for a prison sentence. E.g. ‘Doing his porridge’. The term is most commonly thought to be an allusion to the fact that porridge is, or used to be, a common food in prison. The term is also thought to be a pun on the much older slang word for prison, ‘stir’.: the development of a synthetic cannabinoid market in an English prison. Int J Drug Pol 40:57–69
Article
Google Scholar
Schep LJ, Slaughter RJ, Hudson S, Place R, Watts M (2015) Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol 34:557–560
CAS
PubMed
Article
Google Scholar
Smart R, Caulkins JP, Kilmer B, Davenport S, Midgette G (2017) Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction 112:2167–2177
PubMed
PubMed Central
Article
Google Scholar
Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (phila) 54:1–13
CAS
Article
Google Scholar
UNODC (2015) Global SMART Update Volume 13, March 2015. https://www.unodc.org/unodc/en/scientists/global-smart-update-2015-vol14.html
Ustundag MF, Ozhan Ibis E, Yucel A, Ozcan H (2015) Synthetic cannabis-induced mania. Case Rep Psychiatry 2015:310930
PubMed
PubMed Central
Google Scholar
Van Hout MC, Hearne E (2017) User experiences of development of dependence on the synthetic cannabinoids, 5f-AKB48 and 5F-PB-22, and subsequent withdrawal syndromes. Int J Ment Heal Addict 15:565–579
Article
Google Scholar
Vandrey R, Dunn KE, Fry JA, Girling ER (2012) A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend 120:238–241
CAS
PubMed
Article
Google Scholar
Waugh J, Najafi J, Hawkins L, Hill SL, Eddleston M, Vale JA, Thompson JP, Thomas SHL (2016) Epidemiology and clinical features of toxicity following recreational use of synthetic cannabinoid receptor agonists: a report from the United Kingdom National Poisons Information Service. Clin Toxicol 54:512–518
CAS
Article
Google Scholar
Wilson J, Freeman TP, Mackie CJ (2019) Effects of increasing cannabis potency on adolescent health. The Lancet Child Adoles Health 3:121–128
Article
Google Scholar
Winstock A, Lynskey M, Borschmann R, Waldron J (2015) Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol 29:698–703
PubMed
Article
Google Scholar
Winstock AR, Barratt MJ (2013a) The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol 28:390–393
PubMed
Article
Google Scholar
Winstock AR, Barratt MJ (2013b) Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 131:106–111
CAS
PubMed
Article
Google Scholar
Winstock AR, Kaar S, Borschmann R (2014) Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample. J Psychopharmacol 28:49–54
PubMed
Article
CAS
Google Scholar